Does exogenous glucagon-like peptide-1 (GLP-1) attenuates the glycaemic response to small intestinal nutrient in critically ill patients with pre-existing type-2 diabetes?
The effect of exogenous glucagon-like peptide-1 (GLP-1) compared to placebo on glycaemia in critically ill patients with pre-existing type-2 diabetes during small intestinal feeding
Adam Deane
10 participants
Jul 1, 2009
Interventional
Conditions
Summary
The primary objective of this study is to establish if glucagon-like peptide-1 (a hormone released from the gastrointestinal) has an effect on blood sugar levels in diabetic patients who are critically ill
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Intravenous Glucagon-like peptide-1 (reconstituted in 4%albumin) at 1.2pmol/kg/min will be administered for 270 min at 1ml/min. The infusion will commence 30 minutes prior to the commencement of intestinal nutrient infusion. Seperated by 24 hours the cross-over treatment is placebo (intravenous 4% Albumin at 1ml/min for 270 min), again commenced 30 minutes prior to intestinal nutrient infusion
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12610000185066